Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

被引：35
|
作者：
Giovannoni, Gavin [1 ]
机构：
[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 41卷
关键词：
OCRELIZUMAB;
D O I：
10.1016/j.msard.2020.102135
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The COVID-19 pandemic and the use of MS disease-modifying therapies
    Giovannoni, Gavin
    Hawkes, Chris
    Lechner-Scott, Jeannette
    Levy, Michael
    Waubant, Emmanuelle
    Gold, Julian
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [2] Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases
    Moehn, Nora
    Konen, Franz E.
    Pul, Refik
    Kleinschnitz, Christoph
    Pruss, Harald
    Witte, Torsten
    Stangel, Martin
    Skripuletz, Thomas
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (12) : 1 - 12
  • [3] Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
    Januel, Edouard
    Hajage, David
    Labauge, Pierre
    Maillart, Elisabeth
    De Seze, Jerome
    Zephir, Helene
    Pelletier, Jean
    Guilloton, Laurent
    Bensa, Caroline
    Heinzlef, Olivier
    Casez, Olivier
    Biotti, Damien
    Bourre, Bertrand
    Vukusic, Sandra
    Maurousset, Aude
    Berger, Eric
    Laplaud, David
    Lebrun-Frenay, Christine
    Dubessy, Anne-Laure
    Branger, Pierre
    Thouvenot, Eric
    Clavelou, Pierre
    Sellal, Francois
    Manchon, Eric
    Moreau, Thibault
    Papeix, Caroline
    Tubach, Florence
    Louapre, Celine
    JAMA NETWORK OPEN, 2023, 6 (06) : E2319766
  • [4] Dental Adverse Effects of Anti-CD20 Therapies
    Bartak, Helene
    Fareh, Tasnim
    Ben Othman, Nouha
    Viard, Delphine
    Cohen, Mikael
    Rocher, Fanny
    Ewig, Elliot
    Drici, Milou-Daniel
    Lebrun-Frenay, Christine
    NEUROLOGY AND THERAPY, 2024, 13 (03) : 917 - 930
  • [5] Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection
    Maghbooli, Zhila
    Hosseinpour, Hesham
    Fattahi, Mohammad Reza
    Varzandi, Tarlan
    Hamtaeigashi, Sara
    Mohammad-nabi, Sara
    Aghababaei, Yasaman
    Sahraian, Mohammad Ali
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 67
  • [6] Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study
    Moser, Tobias
    O'Sullivan, Ciara
    Otto, Ferdinand
    Hitzl, Wolfgang
    Pilz, Georg
    Schwenker, Kerstin
    Mrazek, Cornelia
    Haschke-Becher, Elisabeth
    Trinka, Eugen
    Wipfler, Peter
    Harrer, Andrea
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2022, 15
  • [7] A personalized approach for anti-CD20 therapies in multiple sclerosis
    Hogenboom, Laura
    Kempen, Zoe L. E. van
    Kalincik, Tomas
    Bar-Or, Amit
    Killestein, Joep
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [8] Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies
    Carvajal, Rene
    Rodriguez-Acevedo, Breogan
    Garcia-Vasco, Lorena
    Zabalza, Ana
    Arino, Helena
    Bollo, Luca
    Cabello-Clotet, Noemi
    Castillo, Joaquin
    Cobo-Calvo, Alvaro
    Comabella, Manuel
    Falco-Roget, Anna
    Galan, Ingrid
    Garcia-Sarreon, Alexis
    Gomez-Estevez, Irene
    Granados, Galo
    La Puma, Delon
    Chain, Gloria Mato
    Midaglia, Luciana
    Nieto-Garcia, Asuncion
    Otero-Romero, Susana
    Pappolla, Agustin
    Rodriguez, Marta
    Sansano, Irene
    Rio, Jordi
    Tagliani, Paula
    Tur, Carmen
    Vidal-Jordana, Angela
    Vilaseca, Andreu
    Villar, Ana
    Sastre-Garriga, Jaume
    Oreja-Guevara, Celia
    Tintore, Mar
    Montalban, Xavier
    Arrambide, Georgina
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (14) : 1788 - 1801
  • [9] Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
    de Seze, Jerome
    Maillart, Elisabeth
    Gueguen, Antoine
    Laplaud, David A. A.
    Michel, Laure
    Thouvenot, Eric
    Zephir, Helene
    Zimmer, Luc
    Biotti, Damien
    Liblau, Roland
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [10] The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis
    Michael Zhong
    Anneke van der Walt
    Maria Pia Campagna
    Jim Stankovich
    Helmut Butzkueven
    Vilija Jokubaitis
    Neurotherapeutics, 2020, 17 : 1768 - 1784
12345